At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Safety, Tolerability and Impact on Biomarkers of Anti-Oxidant Treatment of Mild to Moderate Alzheimer's Disease
In Brief
A Phase 1 clinical trial evaluating Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, and 2 other interventions for Alzheimer's Disease. Completed, enrolled 75 participants across 13 sites.
Detailed Summary
The purpose of this study is to examine the safety and effectiveness of two anti-oxidant treatment regimens in patients with mild to moderate Alzheimer's disease. The anti-oxidant treatments include vitamin E + C + alpha-lipoic acid, and Coenzyme Q (CoQ).
Study Details
Timeline
Interventions
vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
400 mg, compounded as a wafer, two wafers three times per day with meals
one placebo capsule three times per day with meals
two placebo wafers three times per day with meals